DE3650055T2 - Fibroblast-wachstumsfaktor. - Google Patents

Fibroblast-wachstumsfaktor.

Info

Publication number
DE3650055T2
DE3650055T2 DE3650055T DE3650055T DE3650055T2 DE 3650055 T2 DE3650055 T2 DE 3650055T2 DE 3650055 T DE3650055 T DE 3650055T DE 3650055 T DE3650055 T DE 3650055T DE 3650055 T2 DE3650055 T2 DE 3650055T2
Authority
DE
Germany
Prior art keywords
bfgf
growth factor
fibroblast growth
amino acid
acid residue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE3650055T
Other languages
English (en)
Other versions
DE3650055D1 (de
Inventor
Frederick Esch
Andrew Baird
Peter Bohlen
Denis Gospodarowicz
Nicholas Ling
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Salk Institute for Biological Studies
Original Assignee
Salk Institute for Biological Studies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25003873&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE3650055(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Salk Institute for Biological Studies filed Critical Salk Institute for Biological Studies
Application granted granted Critical
Publication of DE3650055D1 publication Critical patent/DE3650055D1/de
Publication of DE3650055T2 publication Critical patent/DE3650055T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factors [FGF]
    • C07K14/503—Fibroblast growth factors [FGF] basic FGF [bFGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/839—Nerves; brain
DE3650055T 1985-06-20 1986-06-18 Fibroblast-wachstumsfaktor. Expired - Lifetime DE3650055T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/747,154 US4956455A (en) 1984-03-05 1985-06-20 Bovine fibroblast growth factor
PCT/US1986/001318 WO1986007595A1 (en) 1985-06-20 1986-06-18 Fibroblast growth factor

Publications (2)

Publication Number Publication Date
DE3650055D1 DE3650055D1 (de) 1994-10-06
DE3650055T2 true DE3650055T2 (de) 1994-12-15

Family

ID=25003873

Family Applications (1)

Application Number Title Priority Date Filing Date
DE3650055T Expired - Lifetime DE3650055T2 (de) 1985-06-20 1986-06-18 Fibroblast-wachstumsfaktor.

Country Status (7)

Country Link
US (1) US4956455A (de)
EP (2) EP0228449B1 (de)
JP (1) JPH0829097B2 (de)
AT (1) ATE110744T1 (de)
CA (1) CA1341638C (de)
DE (1) DE3650055T2 (de)
WO (1) WO1986007595A1 (de)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5235042A (en) * 1984-02-29 1993-08-10 The Children's Medical Center Corporation Endothelial cell growth factor
US5155214A (en) * 1984-03-05 1992-10-13 The Salk Institute For Biological Studies Basic fibroblast growth factor
US5604293A (en) * 1985-09-12 1997-02-18 Scios Inc. Recombinant human basic fibroblast growth factor
US5439818A (en) * 1985-09-12 1995-08-08 Scios Nova Inc. DNA encoding human recombinant basic fibroblast growth factor
DE3689845T3 (de) * 1985-09-12 2001-11-15 Scios Inc Rekombinanter fibroblast-wachstumsfaktor.
US5859208A (en) * 1988-07-06 1999-01-12 Fiddes; John C. Human basic fibroblast growth factor analog
US4994559A (en) * 1985-12-17 1991-02-19 Synergen, Inc. Human basic fibroblast growth factor
US5026839A (en) * 1985-12-17 1991-06-25 Synergen, Inc DNA encoding a basic fibroblast growth factor
US7223842B1 (en) 1986-08-11 2007-05-29 Massachusetts Eye And Ear Infirmary Detection of proteins whose absence is associated with a neoplasm
US7384735B1 (en) 1986-08-11 2008-06-10 Massachusetts Eye And Ear Infirmary Retinoblastoma nucleic acids
US5853988A (en) * 1986-08-11 1998-12-29 Massachusetts Eye And Ear Infirmary Diagnosis of retinoblastoma
JPH01501840A (ja) * 1987-01-16 1989-06-29 アムジエン・インコーポレーテツド 繊維芽細胞成長因子の産生
US5852177A (en) * 1987-02-24 1998-12-22 Takeda Chemical Industries, Ltd. Basic fibroblast growth factor (bFGF) muteins
JP2526965B2 (ja) * 1987-02-24 1996-08-21 武田薬品工業株式会社 ムテイン，ｄｎａおよびその用途
US5459250A (en) 1987-06-16 1995-10-17 New York University Truncated mammalian growth factor DNA sequence
US5750659A (en) * 1987-06-16 1998-05-12 New York University Mammalian growth factor
DE3721081A1 (de) * 1987-06-26 1989-01-19 Progen Biotechnik Gmbh Dna-sequenz, die codiert fuer ein zellteilungsfoerderndes polypeptid, sowie ein plasmid, ein wirtsorganismus und ein verfahren zur gewinnung dieses polypeptids
AU629176B2 (en) * 1987-07-07 1992-10-01 Scios Nova Inc. Recombinant fibroblast growth factors
KR890701607A (ko) * 1987-11-24 1989-12-21 원본미기재 섬유아세포 성장 인자의 유사체
EP0339905A3 (de) * 1988-04-25 1991-05-08 Ethicon, Inc. Wachstumfaktoren und Retinoiden enthaltende Wundheilungzusammensetzungen
US5126323A (en) * 1989-11-16 1992-06-30 Genetics Institute, Inc. Homogeneous purified k-fgf and compositions containing the same
GB9017008D0 (en) * 1990-08-02 1990-09-19 Erba Carlo Spa Process for the enzymatic preparation of basic fibroblast growth factor
ES2087207T3 (es) * 1990-11-23 1996-07-16 American Cyanamid Co Factor del crecimiento de fibroblasto quimerico.
DE69204990T2 (de) * 1991-01-03 1996-05-15 Salk Inst For Biological Studi Mitotoxin zur behandlung von gefässbeschädigung.
US5206023A (en) * 1991-01-31 1993-04-27 Robert F. Shaw Method and compositions for the treatment and repair of defects or lesions in cartilage
US5492894A (en) * 1991-03-21 1996-02-20 The Procter & Gamble Company Compositions for treating wrinkles comprising a peptide
US5270300A (en) * 1991-09-06 1993-12-14 Robert Francis Shaw Methods and compositions for the treatment and repair of defects or lesions in cartilage or bone
DE4132005A1 (de) * 1991-09-26 1993-04-01 Merck Patent Gmbh Kombination enthaltend wachstumsfaktoren und polyelektrolyte
EP0580874A4 (en) * 1992-02-14 1997-02-26 Kaken Pharma Co Ltd Remedy for airway diseases
GB9203533D0 (en) * 1992-02-19 1992-04-08 Erba Carlo Spa Use of the conjugate between a fibroblast growth factor and a saporin in treating ocular pathologies
US5348941A (en) * 1992-04-01 1994-09-20 Merck & Co., Inc. Stabilizers for fibroblast growth factors
US6551618B2 (en) 1994-03-15 2003-04-22 University Of Birmingham Compositions and methods for delivery of agents for neuronal regeneration and survival
US5795737A (en) * 1994-09-19 1998-08-18 The General Hospital Corporation High level expression of proteins
KR100374310B1 (ko) * 1995-02-14 2003-05-22 주식회사 엘지생명과학 변형된인간염기성섬유아세포성장인자및이의생산방법
EP0832216A4 (de) * 1995-06-05 1999-06-16 Human Genome Sciences Inc Fibroblaster wachstumsfaktor
US5773252A (en) 1995-06-05 1998-06-30 Human Genome Sciences, Inc. Fibroblast growth factor 15
US6274712B1 (en) 1997-12-23 2001-08-14 3-Dimensional Pharmaceuticals, Inc. Analogs of human basic fibroblast growth factor mutated at one or more of the positions glutamute 89, aspartate 101 or leucine 137
CA2339330A1 (en) * 1998-08-13 2000-02-24 University Of Southern California Methods to increase blood flow to ischemic tissue
ES2233101T3 (es) 1998-09-03 2005-06-01 Chiron Corp Dosis unitaria de fgf-2 angiogenicamente efectiva y su utilizacion.
US6440934B1 (en) 1998-10-13 2002-08-27 Chiron Corporation Angiogenically effective unit dose of FGF-2 and method of use
US20020072489A1 (en) * 1998-10-13 2002-06-13 Whitehouse Martha J. Angiogenically effective unit dose of FGF-2 and method of use
US8618052B2 (en) 1998-10-13 2013-12-31 Novartis Vaccines And Diagnostics, Inc. Method of treating coronary artery disease by administering FGF-5
US6451303B1 (en) * 1998-10-13 2002-09-17 Chiron Corporation Method of treating coronary artery disease by administering a recombinant FGF
US20030166550A1 (en) 1999-08-27 2003-09-04 Chiron Corporation Angiogenically effective unit dose of FGF-2 and method of use
WO2001013031A2 (en) * 1999-08-13 2001-02-22 Chiron Corporation Dose of an angiogenic factor and method of administering to improve myocardial blood flow
JP2005503759A (ja) * 2001-01-24 2005-02-10 アメリカ合衆国 幹細胞の膵臓内分泌細胞への分化方法
US20030211605A1 (en) * 2001-05-01 2003-11-13 Lee Sang-Hun Derivation of midbrain dopaminergic neurons from embryonic stem cells
DK1541674T3 (da) 2002-06-18 2011-03-14 Eisai R&D Man Co Ltd Primære dyrkede adipocyter til genterapi
JP2007517042A (ja) 2003-12-30 2007-06-28 デュレクト コーポレーション 活性物質、好ましくはｇｎｒｈの制御放出のための、好ましくはｐｅｇおよびｐｌｇの混合物を含有するポリマーインプラント
CA2695321A1 (en) 2007-08-16 2009-02-26 Andreas Androutsellis-Theotokis Methods for promoting stem cell proliferation and survival
US8623820B2 (en) * 2008-05-02 2014-01-07 University Of Western Ontario FGF-9 and its use relating to blood vessels
EP3323884A1 (de) 2013-02-01 2018-05-23 The United States Of America as Represented by the Secretary, Department of Health an Human Service Verfahren zur erzeugung von zellen im retinalen pigmentepithel aus induzierten pluripotenten stammzellen
US11530388B2 (en) 2017-02-14 2022-12-20 University of Pittsburgh—of the Commonwealth System of Higher Education Methods of engineering human induced pluripotent stem cells to produce liver tissue
JP2022513073A (ja) 2018-11-19 2022-02-07 ザ ユナイテッド ステイツ オブ アメリカ アズ リプリゼンテッド バイ ザ セクレタリー、デパートメント オブ ヘルス アンド ヒューマン サービシーズ 生分解性組織置換インプラントおよびその使用
CA3220433A1 (en) 2021-05-28 2022-12-01 Arvydas Maminishkis Biodegradable tissue scaffold with secondary matrix to host weakly adherent cells
EP4347795A1 (de) 2021-05-28 2024-04-10 The United States of America, as represented by The Secretary, Department of Health and Human Services Verfahren zur erzeugung von makula-, zentralen und peripheren retinapigmentepithelzellen

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3689845T3 (de) * 1985-09-12 2001-11-15 Scios Inc Rekombinanter fibroblast-wachstumsfaktor.
EP0241830A3 (en) * 1986-04-08 1990-01-10 The General Hospital Corporation Hepatoma-derived growth factor
DE4213967A1 (de) * 1992-04-29 1993-11-04 Basf Ag Waessrige polymerisatdispersion

Also Published As

Publication number Publication date
EP0228449B1 (de) 1994-08-31
JPS63500036A (ja) 1988-01-07
US4956455A (en) 1990-09-11
ATE110744T1 (de) 1994-09-15
EP0228449A4 (de) 1989-04-24
DE3650055D1 (de) 1994-10-06
EP0597827A1 (de) 1994-05-18
EP0228449A1 (de) 1987-07-15
JPH0829097B2 (ja) 1996-03-27
CA1341638C (en) 2014-06-17
WO1986007595A1 (en) 1986-12-31

Similar Documents

Publication Publication Date Title
DE3650055D1 (de) Fibroblast-wachstumsfaktor.
NO174351C (no) Fremgangsmåte for fremstilling av human insulinforlöper samt DNA-sekvens og vektor til anvendelse av fremgangsmåten
YU47735B (sh) Postupak za sintezu biološki aktivnih polipeptida limfotoksina
ES8800049A1 (es) Un metodo para la preparacion de eritropoyetina.
NZ335109A (en) Stable analogs of keratinocyte growth factor (KRF) useful for preventing alopecia, treating gastro-duodenal ulcers, bowel disease, liver function or general induction epithelial cell proliferation
ES8704974A1 (es) Procedimiento para la obtencion de derivados de oligopeptido, de efecto tensioactivo compatible con la piel
DE3479734D1 (en) Novel, physiologically active polypeptides and production method thereof
EP0373549A3 (de) Enzym-hemmende Aminosäurederivate, Verfahren zu ihrer Herstellung, diese enthaltende Mittel und ihre Verwendung
EP0326490A3 (en) Synthetic peptides and mixtures thereof for detecting hiv antibodies
NO175872C (no) Plasmidvektor, fremgangsmåte for fremstilling av peptider og myelomcelle
AU6707686A (en) Prostate-derived growth factor
EP0249412A3 (en) C-terminal alpha-amidating enzyme and process for production and use thereof
IE810114L (en) N-benzyloxycarbonyl-l-aspartic acid
ATE78872T1 (de) Herstellung von polypeptiden.
JPS6420086A (en) Polypeptide and production thereof
GR3007491T3 (de)
DE3686981T2 (de) Produktion eines proteins.
ES8801378A1 (es) Un metodo para preparar un vector de expresion que tiene un sistema de replicacion funcional en un microorganismo hospedante
DK157902C (da) Hoejkoncentrerede, vandige aminoxidpraeparater og fremgangsmaade til fremstilling heraf
EP0687685A4 (de) Physiologisch-aktive peptide
PT84011A (fr) Procede de preparation de nouveaux analogues de composes polypeptidiques hypocalcemiants epargnant de calcium de l:organisme
TW243453B (en) Cloning and characterization of a cardiac adenylyl cyclase
ES8603380A1 (es) Un procedimiento para producir cristales de sal equimolar delirina y acido 2-hidroxi-4-metiltiobutirico
ES2000879A6 (es) Un procedimiento para preparar una sal de acido inorganico de cloruro de n-(1(s)-etoxicarbonil-3-fenilpropil)-l-alanilo
ATE52258T1 (de) Verfahren zur herstellung von 2-beta-dribofuranosylselenazol-4-carboxamid.

Legal Events

Date Code Title Description
8363 Opposition against the patent
8365 Fully valid after opposition proceedings